GB2489180B - Predicting capecitabine toxicity - Google Patents

Predicting capecitabine toxicity

Info

Publication number
GB2489180B
GB2489180B GB1212893.0A GB201212893A GB2489180B GB 2489180 B GB2489180 B GB 2489180B GB 201212893 A GB201212893 A GB 201212893A GB 2489180 B GB2489180 B GB 2489180B
Authority
GB
United Kingdom
Prior art keywords
predicting
capecitabine toxicity
capecitabine
toxicity
predicting capecitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1212893.0A
Other versions
GB201212893D0 (en
GB2489180A (en
Inventor
Aathavan Lo-Ganayagam
Jeremy David Sanderson
Anthony Marin Marinaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guys and St Thomas NHS Foundation Trust
Original Assignee
Guys and St Thomas NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guys and St Thomas NHS Foundation Trust filed Critical Guys and St Thomas NHS Foundation Trust
Publication of GB201212893D0 publication Critical patent/GB201212893D0/en
Publication of GB2489180A publication Critical patent/GB2489180A/en
Application granted granted Critical
Publication of GB2489180B publication Critical patent/GB2489180B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
GB1212893.0A 2009-12-21 2010-12-21 Predicting capecitabine toxicity Expired - Fee Related GB2489180B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0922356A GB0922356D0 (en) 2009-12-21 2009-12-21 Predicting capecitabine toxicity
PCT/GB2010/002304 WO2011077080A1 (en) 2009-12-21 2010-12-21 Method of predicting capecitabine toxicity

Publications (3)

Publication Number Publication Date
GB201212893D0 GB201212893D0 (en) 2012-09-05
GB2489180A GB2489180A (en) 2012-09-19
GB2489180B true GB2489180B (en) 2014-03-12

Family

ID=41717349

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0922356A Ceased GB0922356D0 (en) 2009-12-21 2009-12-21 Predicting capecitabine toxicity
GB1212893.0A Expired - Fee Related GB2489180B (en) 2009-12-21 2010-12-21 Predicting capecitabine toxicity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0922356A Ceased GB0922356D0 (en) 2009-12-21 2009-12-21 Predicting capecitabine toxicity

Country Status (2)

Country Link
GB (2) GB0922356D0 (en)
WO (1) WO2011077080A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014137705A1 (en) * 2013-03-05 2014-09-12 The Board Of Trustees Of The Leland Stanford Junior University Assessing risk for encephalopathy induced by 5-fluorouracil or capecitabine
CN104975014A (en) * 2015-07-08 2015-10-14 南昌艾迪康临床检验所有限公司 Primers and method for detecting 79th site, 208th site and 435th site of CDA gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007150069A2 (en) * 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2009021551A1 (en) * 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007150069A2 (en) * 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2009021551A1 (en) * 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, Vol. 63, 2009, MERCIER C ET AL: "Early severe toxicities after capecitabine intake...", Pages 1177-1180 *
CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, Vol. 14, 2008, SHARMA ROHINI ET AL: "Thymidylate synthase and methylene....", Pages 817-825. *
CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, Vol. 27, 2005, WALKO C M ET AL: "Capecitabine: A review", Pages 23-44 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, ELSEVIER SCIENCE IRELAND, Vol. 68, 2008, BONONI A ET AL : "Methylenetetrahydrofolate reductase (MTHFR) gene......", Pages s42-s43 *
CURRENT DRUG METABOLISM MAY 2008 LNKD-PUBMED, Vol. 9, 2008, RIBELLES N ET AL: "A carboxylesterase 2 gene polymorphism....", Pages 336-343. *
JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, Vol. 25, 2007, SUGIYAMA EMIKO ET AL: "Pharmacokinetics of gemcitabine in Japanes cancer patients....", Pages 32-42. *
PHARMACOGENOMICS JOURNAL, NATURE PUBLISHING GROUP, GB, Vol. 5, 2005, MARING J G ET AL: "Genetic factors influencing pyrimidine....", Pages 226-243. *
TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 28, 2007, MERCIER ET AL: "Severe or lethal toxicities upon capecitabine intake...", Pages 597-598 *

Also Published As

Publication number Publication date
GB0922356D0 (en) 2010-02-03
WO2011077080A1 (en) 2011-06-30
GB201212893D0 (en) 2012-09-05
GB2489180A (en) 2012-09-19

Similar Documents

Publication Publication Date Title
HUS2100007I1 (en) Filgotinib or salt
ZA201008829B (en) Nucleoside cyclicphosphates
EP2425609A4 (en) Mid-service sharing
GB0810179D0 (en) Object location
IL215387A0 (en) Application sharing
EP2171388A4 (en) Striker-fired firearm
PL2488062T3 (en) Sliding arrangement
GB2463349B (en) Dart
IL199559A0 (en) Belly armor
EP2490571A4 (en) Partition
IL214327A0 (en) Actagardine derivatives
EP2253924A4 (en) Ammunition
EP2399785A4 (en) Slide arrangement
IL218768A0 (en) Magazine-integrated ammunition
IL202372A0 (en) Armor
GB0913494D0 (en) Shot podz
GB2489180B (en) Predicting capecitabine toxicity
GB0902803D0 (en) Armour
GB2469272B (en) Block
GB2456006B (en) Dartboard arrangement
TWM389844U (en) Gun
IL216320A0 (en) Armor
GB0902945D0 (en) Weapon
GB0904932D0 (en) Handgun extension
PL118467U1 (en) Solid partition

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20161221